NCT03278262View on ClinicalTrials.gov

The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting

CompletedOBSERVATIONAL

Enrollment

2,312

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Wet Macular Degeneration

Interventions

DRUG

Aflibercept (Eylea, BAY86-5321)

Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.

Trial Locations (1)

Unknown

Many locations, Lund